Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Castellano, Daniel ^a   Puente, Javier ^b   de Velasco, Guillermo ^c   Chirivella, Isabel ^d   López Criado, Pilar ^e   Mohedano, Nicolás ^f   Fernández, Ovidio ^g   García Carbonero, Icíar ^h   González, María Belén ⁱ   Grande, Enrique ^j  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c St John's Innovation Centre   (United Kingdom)

^d UNIVERSITY OF VALENCIA   (Spain)

^e MD ANDERSON CANCER CENTER   (Spain)

^f HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^g Hospital de Orense   (Spain)

^h HOSPITAL VIRGEN DE LA SALUD   (Spain)

ⁱ HOSPITAL SON LLÀTZER   (Spain)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

more..

Author keywords

Activity; Community setting; Second line; Urothelial carcinoma; Vinflunine

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; PACLITAXEL; PLATINUM DERIVATIVE; VINFLUNINE; ANTINEOPLASTIC AGENT; VINBLASTINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE METASTASIS; CLINICAL PRACTICE; COMORBIDITY; CONSTIPATION; DIABETES MELLITUS; DISTANT METASTASIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TREATMENT FAILURE; ECOG PERFORMANCE STATUS; FOLLOW UP; FUNCTIONAL STATUS ASSESSMENT; HUMAN; HYPERTENSION; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OBSERVATIONAL STUDY; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TIME TO TUMOR PROGRESSION; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; UROGENITAL TRACT CANCER; VOMITING; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, TRANSITIONAL CELL; FEMALE; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; RETREATMENT; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; RETREATMENT; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 84929939532     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-779     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
2. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005, 23(21):4602-4608.
3. Roberts JT, von der Maase H, Sengeløv L, Conte PF, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M: Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/ vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol 2006, 17:118-122.
4. Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C, Paz-Ares L, Laufman LR, Winquist E, Raghavan D, Marreaud S, Collette S, Sylvester R, de Wit R: Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/ cisplatin inpatients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012, 30(10):1107-1113.
5. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M, National Comprehensive Cancer Network (NCCN): Bladder cancer. J Natl Compr Canc Netw 2013, 11(4):446-475.
6. Bellmunt J, Petrylak DP: New therapeutic challenges in advanced bladdercancer. Semin Oncol 2012, 39(5):598-607.
7. Castellano D, Carles J, Esteban E, Trigo JM, Climent Má, Maroto JP, del Muro XG, Font A, Paz-Ares L, Arranz Já, Bellmunt J: Recommendations for the optimal management of early and advanced urothelial carcinoma. Cancer Treat Rev 2012, 38(5):431-441.
8. Bellmunt J, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V: Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22:45-49.
9. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB: Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002, 20(4):937-940.
10. Ko YJ, Canil CM, Mukherjee SD, Winquist E, Elser C, Eisen A, Reaume MN, Zhang L, Sridhar SS: Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol 2013, 14(8):769-776.
11. Beer TM, Goldman B, Nichols CR, Petrylak DP, Agarwal M, Ryan CW, Crawford ED, Southwest Oncology Group: Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy. Clin Genitourin Cancer 2008, 6(1):36-39.
12. Dreicer R, Li S, Manola J, Haas NB, Roth BJ, Wilding G, Eastern Cooperative Oncology Group: Phase 2 trial of epothilone Banalog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer 2007, 110(4):759-763.
13. Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl RJ, Millard F, Bajorin DF, Small EJ, Cancer and Leukemia Group B: Phase II study of bortezomib inpatients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Ann Oncol 2008, 19(5):946-950.
14. Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF: Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007, 25(3):265-270.
15. Winquist E, Vokes E, Moore MJ, Schumm LP, Hoving K, Stadler WM: A Phase II study of oxaliplatin in urothelial cancer. Urol Oncol 2005, 23(3):150-154.
16. Witte RS, Elson P, Bono B, Knop R, Richardson RR, Dreicer R, Loehrer PJ Sr: Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997, 15(2):589-593.
17. Wülfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, Beuzeboc P, Parikh R, Pétavy F, El-Hariry IA: A single-arm, multicenter, open label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009, 115(13):2881-2890.
18. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997, 15(5):1853-1857.
19. Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, Oliva C, Pacini M, De Lena M: A phase II study of gemcitabine inpatients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998, 34(8):1208-1212.
20. Witte RS, Manola J, Burch PA, Kuzel T, Weinshel EL, Loehrer PJ Sr: Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial. Invest New Drugs 1998, 16(2):191-195.
21. Petrylak DP, Tangen CM, Van Veldhuizen PJ, Jr GJW, Twardowski PW, Atkins JN, Kakhil SR, Lange MK, Mansukhani M, Crawford ED: Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839for advanced transitional cell carcinoma of the urothelium. BJU Int 2010, 105(3):317-321.
22. Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, Wilding G: Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009, 115(18):4090-4095.
23. Gallagher DJ, Al-Ahmadie H, Ostrovnaya I, Gerst SR, Regazzi A, Garcia-Grossman I, Riches J, Gounder SK, Flaherty AM, Trout A, Milowsky MI, Bajorin DF: Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response. Eur Urol 2011, 60(2):344-349.
24. Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C, Vaishampayan U: A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase Inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer 2013.
25. Meluch AA, Burris HS, Greco FA, Hainsworth JD: Gemcitabine and paclitaxel combination therapy in transitional cell carcinoma of the urothelium. Eur J Cancer 2000, 36:30-33.
26. Milowsky MI, Nanus DM, Maluf FC, Mironov S, Shi W, Iasonos A, Riches J, Regazzi A, Bajorin DF: Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol 2009, 27(25):4062-4067.
27. Kouno T, Ando M, Yonemori K, Matsumoto K, Shimizu C, Katsumata N, Komiyama M, Okajima E, Matsuoka N, Fujimoto H, Fujiwara Y: Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol 2007, 52(4):1115-1122.
28. Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ: Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 2010, 11(9):861-870.
29. Aparicio LM, Pulido EG, Gallego GA: Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity. Anticancer Drugs 2012, 23(1):1-11.
30. Braguer D, Barret JM, McDaid H, Kruczynski A: Antitumor activity of vinflunine: effector pathways and potential for synergies. Semin Oncol 2008, 35:S13-S21.
31. Kruczynski A, Hill BT: Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 2001, 40(2):159-173.
32. Coderch C, Morreale A, Gago F: Tubulin-based structure-affinity relationships for antimitotic Vinca alkaloids. Anticancer Agents Med Chem 2012, 12(3):219-225.
33. Culine S, Theodore C, De Santis M, Bui B, Demkow T, Lorenz J, Rolland F, Delgado FM, Longerey B, James N: A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containingregimen. Br J Cancer 2006, 94(10):1395-1401.
34. Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, Smith DC, Ringuette S, de Wit E, Pautret V, George C: Vinflunine in platinum pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 2009, 115(18):4110-4117.
35. Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009, 27(27):4454-4461.
36. Bellmunt J, Fougeray R, Rosenberg JE, von der Maase H, Schutz FA, Salhi Y, Culine S, Choueiri TK: Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patient safter failure of platinum-based chemotherapy. Ann Oncol 2013, 24(6):1466-1472.
37. Jessen C, Agerbaek M, Von Der Maase H: Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy. Acta Oncol 2009, 48(3):411-417.
38. Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE: Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010, 28(11):1850-1855.
39. Hegele A, de Geeter P, Goebell P, Matz U, de Schultz W, Retz M: Vinflunine in routine practice for the treatment of advanced or metastatic urothelial cell carcinoma in Germany. Eur J Cancer 2013, 49(Supplement 2):S669.
40. Medioni J, Guillot A, Spaeth D, Di Palma M, Theodore C: Historical data in real life from patients treated by vinflunine for an advanced or metastatic urothelial carcinoma: Results of the CURVE study. Eur J Cancer 2013, Supplement 2:S646-S647.